ArticleHuman vaccines & immunotherapeutics2025

Cost-effectiveness analysis of nirsevimab for prevention of respiratory syncytial virus disease among infants in Shanghai, China: A modeling study.

Qiang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.